Literature DB >> 17391064

Enzymatic properties of human kallikrein-related peptidase 12 (KLK12).

Nader Memari1, Weiping Jiang, Eleftherios P Diamandis, Liu-Ying Luo.   

Abstract

Human kallikrein-related peptidase 12 (KLK12) is a new member of the human tissue kallikrein family. Preliminary studies suggest that KLK12 is differentially expressed in breast cancer and may have potential use as a cancer biomarker. It has been predicted that KLK12 is a secreted serine protease. However, the enzymatic properties of this protein have not been reported so far. Here, we report the production of recombinant KLK12 and analyses of its enzymatic characteristics, including zymogen activation, substrate specificity, and regulation of its activity. KLK12 is secreted as an inactive pro-enzyme, which is able to autoactivate to gain enzymatic activity. Through screening of a panel of fluorogenic and chromogenic peptide substrates, we establish that active KLK12 possesses trypsin-like activity, cleaving peptide bonds after both arginine and lysine. Active KLK12 quickly loses its activity due to autodegradation, and its activity can also be rapidly inhibited by zinc ions and by alpha2-antiplasmin through covalent complex formation. Furthermore, we demonstrate that KLK12 is able to activate KLK11 zymogen in vitro. Our results indicate that KLK12 may participate in enzymatic cascades involving other kallikreins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391064     DOI: 10.1515/BC.2007.049

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  10 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 2.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

3.  Clinical significance of human kallikrein 12 gene expression in gastric cancer.

Authors:  En-Hao Zhao; Zhi-Yong Shen; Hua Liu; Xin Jin; Hui Cao
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

4.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

6.  Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.

Authors:  Maroulio Talieri; Marina Devetzi; Andreas Scorilas; Eleana Pappa; Nikolaos Tsapralis; Ioannis Missitzis; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-02-21

Review 7.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

8.  Human kallikrein-related peptidase 12 stimulates endothelial cell migration by remodeling the fibronectin matrix.

Authors:  T Kryza; C Parent; J Pardessus; A Petit; J Burlaud-Gaillard; P Reverdiau; S Iochmann; V Labas; Y Courty; N Heuzé-Vourc'h
Journal:  Sci Rep       Date:  2018-04-20       Impact factor: 4.379

9.  Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1.

Authors:  Aleksandra Milewska; Katherine Falkowski; Magdalena Kulczycka; Ewa Bielecka; Antonina Naskalska; Pawel Mak; Adam Lesner; Marek Ochman; Maciej Urlik; Elftherios Diamandis; Ioannis Prassas; Jan Potempa; Tomasz Kantyka; Krzysztof Pyrc
Journal:  Sci Signal       Date:  2020-11-24       Impact factor: 8.192

10.  Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Authors:  Jon A Kenniston; Ryan R Faucette; Diana Martik; Stephen R Comeau; Allison P Lindberg; Kris J Kopacz; Gregory P Conley; Jie Chen; Malini Viswanathan; Niksa Kastrapeli; Janja Cosic; Shauna Mason; Mike DiLeo; Jan Abendroth; Petr Kuzmic; Robert C Ladner; Thomas E Edwards; Christopher TenHoor; Burt A Adelman; Andrew E Nixon; Daniel J Sexton
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.